Trastuzumab Deruxtecan Shows Sensitivity in Various Levels of HER2-Expressing Gastric Cancer Cells
April 10th 2021Trastuzumab deruxtecan has not only demonstrated efficacy as a potential anti-HER2 therapeutic option for patients with HER2-amplified gastric cancers, but has also shown promise in those with HER2 moderate-, low-, and non-expressing disease.
Dr. Besse on the Safety of Selpercatinib in Advanced RET+ Thyroid Cancer, NSCLC
April 10th 2021Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.
Copanlisib/Rituximab Improves PFS in Relapsed Indolent Non-Hodgkin Lymphoma
The combination of copanlisib and rituximab was associated with a 48% reduction in the risk of disease progression or death compared with rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.
Germline Variants Associated With High Heritability and Poor Outcomes in Neuroblastoma
April 10th 2021The presence of pathogenic or likely pathogenic germline variants in cancer predisposition genes, which were identified in approximately 1 in 5 patients with neuroblastoma and were mostly inherited, was shown to correlate with worse event-free survival and overall survival vs the absence of germline variants.
Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib and adagrasib in preclinical models.
Double PIK3CA Mutations in Breast Cancer Increase Sensitivity to PI3Kα Inhibition
June 24th 2020Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.
Nivolumab/Ipilimumab Demonstrates OS Benefit in Advanced NSCLC With Brain Metastases
The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.
Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC
June 24th 2020Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.
Tucatinib Produces Potent Preclinical Antitumor Activity, CNS Penetrance in HER2+ Breast Cancer
June 23rd 2020The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.
SM-88 Shows Promising Preclinical Antitumor Activity Across Several Cancers
June 23rd 2020The oral modified dysfunctional tyrosine SM-88 has demonstrated antitumor activity and appears to broadly effect the immune dynamics of the tumor microenvironment, according to early data from 2 xenograft studies.
ctDNA Clearance Shows Correlation With PFS Improvement in EGFR+/MET+ NSCLC
June 23rd 2020Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.
COVID-19 Pandemic Accelerates RWD-Based Initiatives in Oncology
June 23rd 2020The FDA is presently spearheading several initiatives in light of COVID-19 aimed at refining the role of RWD in cancer care to guide clinical trial development, procure answers to pressing clinical questions, and support regulatory decisions for in vitro diagnostics.
Enfortumab Vedotin Demonstrates Additional Mechanisms of Action in UC Models
June 23rd 2020In urothelial carcinoma models, enfortumab vedotin-ejfv appeared to promote multiple mechanisms of action such as bystander cell killing, supporting the use of the agent either alone or in combination with pembrolizumab.
Suggested Benefit of Novel BTK Inhibitor Observed in MCL Models and in NHL Combo Regimen
In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.